The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or placebo (53 individuals) added to standard-of-care oral corticosteroids.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease Sanofi and Regeneron’s Dupixent ...

The possibility of bullous pemphigoid was also unlikely, given that the blister was located on "a single distal extremity," the researchers said.

The many different types of BP can cause difficulty in diagnosis, especially in the variants that present similarly to other dermatological diseases. Generalized erythroderma BP (GEBP) presents ...

Treatment and Prognosis Patients with BP will often go into remission if young, usually less than 65 years old, and in good health, but erupting blisters can continue for 10 or more years. About ...

Direct immunofluorescence biopsy may be a useful tool in the diagnosis of pediatric patients with potential immune-mediated skin disorders.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.